001     186218
005     20240229145736.0
024 7 _ |a 10.1016/j.celrep.2022.111761
|2 doi
024 7 _ |a pmid:36476851
|2 pmid
024 7 _ |a 2211-1247
|2 ISSN
024 7 _ |a 2639-1856
|2 ISSN
024 7 _ |a altmetric:139743123
|2 altmetric
037 _ _ |a DKFZ-2022-03015
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Orth, Martin F
|b 0
245 _ _ |a Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation.
260 _ _ |a [New York, NY]
|c 2022
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1670848912_19724
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:B410#
520 _ _ |a Ewing sarcoma (EwS) is characterized by EWSR1-ETS fusion transcription factors converting polymorphic GGAA microsatellites (mSats) into potent neo-enhancers. Although the paucity of additional mutations makes EwS a genuine model to study principles of cooperation between dominant fusion oncogenes and neo-enhancers, this is impeded by the limited number of well-characterized models. Here we present the Ewing Sarcoma Cell Line Atlas (ESCLA), comprising whole-genome, DNA methylation, transcriptome, proteome, and chromatin immunoprecipitation sequencing (ChIP-seq) data of 18 cell lines with inducible EWSR1-ETS knockdown. The ESCLA shows hundreds of EWSR1-ETS-targets, the nature of EWSR1-ETS-preferred GGAA mSats, and putative indirect modes of EWSR1-ETS-mediated gene regulation, converging in the duality of a specific but plastic EwS signature. We identify heterogeneously regulated EWSR1-ETS-targets as potential prognostic EwS biomarkers. Our freely available ESCLA (http://r2platform.com/escla/) is a rich resource for EwS research and highlights the power of comprehensive datasets to unravel principles of heterogeneous gene regulation by chimeric transcription factors.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CP: Cancer
|2 Other
650 _ 7 |a ChiP-seq
|2 Other
650 _ 7 |a EWSR1-ERG
|2 Other
650 _ 7 |a EWSR1-ETS
|2 Other
650 _ 7 |a EWSR1-FLI1
|2 Other
650 _ 7 |a Ewing sarcoma
|2 Other
650 _ 7 |a enhancer
|2 Other
650 _ 7 |a microsatellites
|2 Other
650 _ 7 |a multi-omics
|2 Other
650 _ 7 |a pediatric sarcoma
|2 Other
650 _ 7 |a tumor heterogeneity
|2 Other
700 1 _ |a Surdez, Didier
|b 1
700 1 _ |a Faehling, Tobias
|0 P:(DE-He78)40245f2168b87c014e445cabf610fd46
|b 2
|u dkfz
700 1 _ |a Ehlers, Anna
|0 P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1
|b 3
|u dkfz
700 1 _ |a Marchetto, Aruna
|b 4
700 1 _ |a Grossetête, Sandrine
|b 5
700 1 _ |a Volckmann, Richard
|b 6
700 1 _ |a Zwijnenburg, Danny A
|b 7
700 1 _ |a Gerke, Julia S
|b 8
700 1 _ |a Zaidi, Sakina
|b 9
700 1 _ |a Alonso, Javier
|b 10
700 1 _ |a Sastre, Ana
|b 11
700 1 _ |a Baulande, Sylvain
|b 12
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 13
|u dkfz
700 1 _ |a Cidre-Aranaz, Florencia
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Ohmura, Shunya
|0 P:(DE-He78)c25b54b0c834093d1f884d2615e305d6
|b 15
|u dkfz
700 1 _ |a Kirchner, Thomas
|0 P:(DE-He78)fd68f49dada874ac262fadf9fde869df
|b 16
|u dkfz
700 1 _ |a Hauck, Stefanie M
|b 17
700 1 _ |a Reischl, Eva
|b 18
700 1 _ |a Gymrek, Melissa
|b 19
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 20
|u dkfz
700 1 _ |a Strauch, Konstantin
|b 21
700 1 _ |a Koster, Jan
|b 22
700 1 _ |a Delattre, Olivier
|b 23
700 1 _ |a Grünewald, Thomas
|0 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
|b 24
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.celrep.2022.111761
|g Vol. 41, no. 10, p. 111761 -
|0 PERI:(DE-600)2649101-1
|n 10
|p 111761
|t Cell reports
|v 41
|y 2022
|x 2211-1247
909 C O |o oai:inrepo02.dkfz.de:186218
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)40245f2168b87c014e445cabf610fd46
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)c25b54b0c834093d1f884d2615e305d6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)fd68f49dada874ac262fadf9fde869df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL REP : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-26T13:08:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-26T13:08:57Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-26T13:08:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL REP : 2021
|d 2022-11-17
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-17
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-17
920 2 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK MU LMU zentral
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B410-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21